Esthesioneuroblastoma: A case with prolonged disease control
Abstract
Keywords
Full Text:
PDFReferences
Berger L, Luc R, Richard D. L’esthesioneuroepitheliome olfactif (French) [Olfactory neuroblastoma]. Bull Assoc Etude Cancer 1924; 13: 410–421.
Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: A general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997; 17(4A): 2683–2706.
Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuro-blastoma: A meta-analysis and review. Lancet Oncol 2001; 2(11): 683–690. doi: 10.1016/S1470-2045(01)00558-7.
Kadish S, Goodman M, Wang CC. Olfactory neuroblas-toma—A clinical analysis of 17 cases. Cancer 1976; 37(3): 1571–1576. doi: 10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L.
Su SY, Bell D, Hanna EY. Esthesioneuroblastoma, neu-roendocrine carcinoma, and sinonasal undifferentiated carcinoma: Differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol 2014; 18(Suppl 2): S149–S156. doi: 10.1055/s-0034-1390014.
Kumar M, Fallon RJ, Hill JS, Davis MM. Esthesioneuroblastoma in children. J Pediat Hematol Onc 2002; 24(6): 482–487. doi: 10.1097/00043426-200208000-00015.
Faragalla H, Weinreb I. Olfactory neuroblastoma: A review and update. Adv Anat Pathol 2009; 16(5): 322–331. doi: 10.1097/PAP.0b013e3181b544cf.
Ow TJ, Bell D, Kupferman ME, DeMonte F, Hanna EY. Esthesioneuroblastoma. Neurosurg Clin N Am 2013; 24(1): 51–65. doi: 10.1016/j.nec.2012.08.005.
Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthe-sioneuroblastoma: A population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 2007; 133(3): 276–280. doi: 10.1001/archotol.133. 3.276.
Dulguerov P, Calcaterra T. Esthesioneuroblastoma: The UCLA experience 1970–1990. Laryngoscope 1992; 102(8): 843–849. doi: 10.1288/00005537-199208000-00001.
Bachar G, Goldstein DP, Shah M, Tandon A, Ringash J, et al. Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head Neck 2008; 30(12): 1607– 1614. doi: 10.1002/hed.20920.
Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, et al. Esthesioneuroblastoma: Continued follow-up of a single institution’s experience. Arch Otolaryngol Head Neck Surg 2006; 132(2): 134–138. doi: 10.1001/archotol. 132.2.134.
Hirose T, Scheithauer BW, Lopes MBS, Gerber HA, Al-termatt HJ, et al. Olfactory neuroblastoma. An immuno-histochemical, ultrastructural, and flow cytometric study. Cancer 1995; 76(1): 4–19. doi: 10.1002/1097-0142 (19950701)76:1<4::AID-CNCR2820760103>3.0.CO;2-E.
Pickuth D, Heywang-Köbrunner SH, Spielmann RP. Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: An analysis of 22 cases. Clin Otolaryngol Allied Sci 1999; 24(5): 457–461. doi: 10.1046/j.1365-2273.1999.00295.x.
Derdeyn CP, Moran CJ, Wippold FJ 2nd, Chason DP, Koby MB, et al. MRI of esthesioneuroblastoma. J Comput Assist Tomogr 1994; 18(1): 16–21.
Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, et al. Esthesioneuroblastoma: Prognosis and management. Neurosurgery 1993; 32(5): 706–715. doi: 10.1097/00006 123-199305000-00002.
Eden BV, Debo RF, Larner JM, Kelly MD, Levine PA, et al. Esthesioneuroblastoma: Long term outcome and patterns of failure — the University of Virginia experience. Cancer 1994; 73(10): 2556–2562. doi: 10.1002/1097-0142(1994 0515)73:10<2556::AID-CNCR2820731017>3.0.CO;2-S.
Ingeholm P, Theilgaard SA, Buchwald C, Hansen HS, Francis D. Esthesioneuroblastoma: A Danish clinico-pathological study of 40 consecutive cases. APMIS 2002; 110(9): 639–645. doi: 10.1034/j.1600-0463.2002.1100907.x.
Dias FL, Sá GM, Lima RA, Kligerman J, Leôncio MP, et al. Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg 2003; 129(11): 1186–1192. doi: 10.1001/archotol.129.11.1186.
Patel SG, Singh B, Stambuk HE, Carlson D, Bridger PG, et al. Craniofacial surgery for esthesioneuroblastoma: Report of an international collaborative study. J Neurol Surg B Skull Base 2012; 73(3): 208–220. doi: 10.1055/ s-0032-1311754.
Gruber G, Laedrach K, Baumert B, Caversaccio M, Raveh J, et al. Esthesioneuroblastoma: Irradiation alone and surgery alone are not enough. Int J Radiat Oncol Biol Phys 2002; 54(2): 486–491. doi: 10.1016/S0360-3016(02) 02941-3.
Chao KS, Kaplan C, Simpson JR, Haughey B, Spector GJ, et al. Esthesioneuroblastoma: The impact of treatment modality. Head Neck 2001; 23(9): 749–757. doi: 10.1002/ hed.1107.
Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, et al. Outcome and prognostic factors in ol-factory neuroblastoma: A rare cancer network study. Int J Radiat Oncol Biol Phys 2010; 78(4): 992–997. doi: 10. 1016/j.ijrobp.2009.09.019.
Devaiah AK, Andreoli MT. Treatment of esthesioneuro-blastoma: A 16-year meta-analysis of 361 patients. Laryngoscope 2009; 119(7): 1412–1416. doi: 10.1002/lary.20280.
Nichols AC, Chan AW, Curry WT, Barker FG, Deschler DG, et al. Esthesioneuroblastoma: The Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. Skull Base 2008; 18(5): 327–337. doi: 10.1055/s-2008-1076098.
Diaz EM Jr, Johnigan RH III, Pero C, El-Naggar AK, Roberts DB, et al. Olfactory neuroblastoma: The 22-year experience at one comprehensive cancer center. Head Neck 2005; 27(2): 138–149. doi: 10.1002/hed.20127.
Ward PD, Heth JA, Thompson BG, Marentette LJ. Esthesioneuroblastoma: Results and outcomes of a single institution’s experience. Skull Base 2009; 19(2): 133–140. doi: 10.1055/s-0028-1096195.
Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: Past, present, and future? Laryngoscope 2003; 113(3): 502–507. doi: 10.1097/00005537-200303000-00020.
Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, et al. Esthesioneuroblastoma: A Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol 2003; 123(3): 433–439. doi: 10.1080/00016480310001295.
Levine PA, McLean WC, Cantrell RW. Esthesioneuroblastoma: The University of Virginia experience 1960– 1985. Laryngoscope 1986; 96(7): 742–746. doi: 10.1288/ 00005537-198607000-00008.
Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys 2009; 73(2): 424–432. doi: 10.1016/j.ijrobp.2008. 04.037.
Noh OK, Lee SW, Yoon SM, Kim SB, Kim SY, et al. Radiotherapy for esthesioneuroblastoma: Is elective nodal irradiation warranted in the multimodality treatment approach? Int J Radiat Oncol Biol Phys 2011; 79(2): 443– 449. doi: 10.1016/j.ijrobp.2009.10.067.
Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, Mcintyre J, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chem-otherapy, surgery, and combined proton-photon radio-therapy. Cancer 2002; 94(10): 2623–2624. doi: 10.1002/ cncr.10537.
Zappia JJ, Carroll WR, Wolf GT, Thornton AF, Ho L, et al. Olfactory neuroblastoma: The results of modern treatment approaches at the University of Michigan. Head Neck 1993; 15(3): 190–196. doi: 10.1002/hed.2880150303.
Argiris A, Dutra J, Tseke P, Haines K. Esthesioneuro-blastoma: The Northwestern University experience. Laryngoscope 2003; 113(1): 155–160. doi: 10.1097/00005537-200301000-00029.
Wade PM Jr, Smith RE, Johns ME. Response of esthesioneuroblastoma to chemotherapy. Report of five cases and review of the literature. Cancer 1984; 53(5): 1036– 1041. doi: 10.1002/1097-0142(19840301)53:5<1036::AID-CNCR2820530504>3.0.CO;2-3.
Resto VA, Eisele DW, Forastiere A, Zahurak M, Lee DJ, et al. Esthesioneuroblastoma: The Johns Hopkins experience. Head Neck 2000; 22(6): 550–558. doi: 10.1002/ 1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0.
Sheehan JM, Sheehan JP, Jane JA Sr, Polin RS. Chemo-therapy for esthesioneuroblastomas. Neurosurg Clin N Am 2000; 11(4): 693–701.
Kiyota N, Tahara M, Fujii S, Kawashima M, Ogino T, et al. Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: A retrospective analysis of 12 cases. Cancer 2008; 112(4): 885–891. doi: 10.1002/cncr.23246.
Turano S, Mastroianni C, Manfredi C, Biamonte R, Ceniti S, et al. Advanced adult esthesioneuroblastoma success-fully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine. J Neurooncol 2010; 98(1): 131–135. doi: 10.1007/s11060-009-0052-9.
DOI: http://dx.doi.org/10.30564/amor.v2i5.83
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Andreia Coelho, Lúcia Águas, Lígia Osório, Paulo Linhares

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.